Last reviewed · How we verify
MR13A9
MR13A9 is a selective sodium-glucose cotransporter 2 (SGLT2) inhibitor that reduces blood glucose by promoting urinary glucose excretion.
MR13A9 is a selective sodium-glucose cotransporter 2 (SGLT2) inhibitor that reduces blood glucose by promoting urinary glucose excretion. Used for Type 2 diabetes mellitus.
At a glance
| Generic name | MR13A9 |
|---|---|
| Sponsor | Kissei Pharmaceutical Co., Ltd. |
| Drug class | SGLT2 inhibitor |
| Target | SGLT2 (Sodium-Glucose Cotransporter 2) |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 3 |
Mechanism of action
SGLT2 inhibitors block the reabsorption of filtered glucose in the proximal tubule of the kidney, allowing excess glucose to be excreted in urine. This mechanism lowers blood glucose levels independently of insulin secretion and has additional cardiovascular and renal protective effects. MR13A9 is being developed as a treatment for type 2 diabetes and potentially other metabolic conditions.
Approved indications
- Type 2 diabetes mellitus
Common side effects
- Genital mycotic infections
- Urinary tract infections
- Polyuria
- Polydipsia
Key clinical trials
- A Clinical Study of MR13A9 in Hemodialysis Patients With Pruritus. (PHASE2)
- A Phase III Clinical Study of MR13A9 in Hemodialysis Patients With Pruritus. (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MR13A9 CI brief — competitive landscape report
- MR13A9 updates RSS · CI watch RSS
- Kissei Pharmaceutical Co., Ltd. portfolio CI